Margaret Rosenfeld

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6274230/publications.pdf

Version: 2024-02-01

208 papers	18,202 citations	15504 65 h-index	14759 127 g-index
210 all docs	210 docs citations	210 times ranked	12203 citing authors

#	Article	IF	Citations
1	Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement. American Journal of Respiratory and Critical Care Medicine, 2019, 200, e70-e88.	5.6	1,812
2	Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatric Pulmonology, 2002, 34, 91-100.	2.0	910
3	Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation. Journal of Pediatrics, 2017, 181, S4-S15.e1.	1.8	572
4	Longitudinal Assessment ofPseudomonas aeruginosain Young Children with Cystic Fibrosis. Journal of Infectious Diseases, 2001, 183, 444-452.	4.0	520
5	Recommendations for a Standardized Pulmonary Function Report. An Official American Thoracic Society Technical Statement. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1463-1472.	5.6	450
6	Failure to Recover to Baseline Pulmonary Function after Cystic Fibrosis Pulmonary Exacerbation. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 627-632.	5.6	445
7	Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis*. Pediatric Pulmonology, 2001, 32, 356-366.	2.0	361
8	Cystic Fibrosis Foundation Evidence-Based Guidelines for Management of Infants with Cystic Fibrosis. Journal of Pediatrics, 2009, 155, S73-S93.	1.8	360
9	Gender Gap in Cystic Fibrosis Mortality. American Journal of Epidemiology, 1997, 145, 794-803.	3.4	335
10	ERS/ATS technical standard on interpretive strategies for routine lung function tests. European Respiratory Journal, 2022, 60, 2101499.	6.7	323
11	Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis. , 1999, 28, 321-328.		306
12	Significant Microbiological Effect of Inhaled Tobramycin in Young Children with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2003, 167, 841-849.	5.6	300
13	Diagnosis, monitoring, and treatment of primary ciliary dyskinesia: PCD foundation consensus recommendations based on state of the art review. Pediatric Pulmonology, 2016, 51, 115-132.	2.0	297
14	Identification of Human Glucocorticoid Receptor Complementary DNA Clones by Epitope Selection. Science, 1985, 228, 740-742.	12.6	286
15	Diagnosis of Primary Ciliary Dyskinesia. An Official American Thoracic Society Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2018, 197, e24-e39.	5.6	285
16	Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2â€“5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study. Lancet Respiratory Medicine,the, 2016, 4, 107-115.	10.7	284
17	Defining a pulmonary exacerbation in cystic fibrosis. Journal of Pediatrics, 2001, 139, 359-365.	1.8	265
18	Developing Cystic Fibrosis Lung Transplant Referral Criteria Using Predictors of 2-Year Mortality. American Journal of Respiratory and Critical Care Medicine, 2002, 166, 1550-1555.	5.6	255

#	Article	IF	Citations
19	Efficacy and safety of lumacaftor and ivacaftor in patients aged 6â€“11 years with cystic fibrosis homozygous for F508del-CFTR : a randomised, placebo-controlled phase 3 trial. Lancet Respiratory Medicine,the, 2017, 5, 557-567.	10.7	243
20	Standardizing Nasal Nitric Oxide Measurement as a Test for Primary Ciliary Dyskinesia. Annals of the American Thoracic Society, 2013, 10, 574-581.	3.2	222
21	Clinical Features of Childhood Primary Ciliary Dyskinesia by Genotype and Ultrastructural Phenotype. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 316-324.	5.6	214
22	Pulmonary exacerbations are associated with subsequent FEV₁ decline in both adults and children with cystic fibrosis. Pediatric Pulmonology, 2011, 46, 393-400.	2.0	211
23	Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study. Lancet Respiratory Medicine,the, 2018, 6, 545-553.	10.7	205
24	Comparative Efficacy and Safety of 4 Randomized Regimens to Treat EarlyPseudomonas aeruginosaInfection in Children With Cystic Fibrosis. JAMA Pediatrics, 2011, 165, 847.	3.0	199
25	Mutations ofDNAH11in patients with primary ciliary dyskinesia with normal ciliary ultrastructure. Thorax, 2012, 67, 433-441.	5.6	198
26	Cystic Fibrosis Foundation Pulmonary Guideline. Pharmacologic Approaches to Prevention and Eradication of Initial Pseudomonas aeruginosa Infection. Annals of the American Thoracic Society, 2014, 11, 1640-1650.	3.2	197
27	Laterality Defects Other Than Situs Inversus Totalis in Primary Ciliary Dyskinesia. Chest, 2014, 146, 1176-1186.	0.8	192
28	Mutations in RSPH1 Cause Primary Ciliary Dyskinesia with a Unique Clinical and Ciliary Phenotype. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 707-717.	5.6	191
29	Zebrafish Ciliopathy Screen Plus Human Mutational Analysis Identifies C21orf59 and CCDC65 Defects as Causing Primary Ciliary Dyskinesia. American Journal of Human Genetics, 2013, 93, 672-686.	6.2	184
30	ZMYND10 Is Mutated in Primary Ciliary Dyskinesia and Interacts with LRRC6. American Journal of Human Genetics, 2013, 93, 336-345.	6.2	183
31	Cystic Fibrosis Foundation Practice Guidelines for the Management of Infants with Cystic Fibrosis Transmembrane Conductance Regulator-Related Metabolic Syndrome during the First Two Years of Life and Beyond. Journal of Pediatrics, 2009, 155, S106-S116.	1.8	176
32	Mutations inCCDC39andCCDC40are the Major Cause of Primary Ciliary Dyskinesia with Axonemal Disorganization and Absent Inner Dynein Arms. Human Mutation, 2013, 34, 462-472.	2.5	176
33	Inhaled Hypertonic Saline in Infants and Children Younger Than 6 Years With Cystic Fibrosis. JAMA - Journal of the American Medical Association, 2012, 307, 2269-77.	7.4	175
34	Cystic fibrosis lung disease starts in the small airways: Can we treat it more effectively?. Pediatric Pulmonology, 2010, 45, 107-117.	2.0	161
35	An Official American Thoracic Society Workshop Report: Optimal Lung Function Tests for Monitoring Cystic Fibrosis, Bronchopulmonary Dysplasia, and Recurrent Wheezing in Children Less Than 6 Years of Age. Annals of the American Thoracic Society, 2013, 10, S1-S11.	3.2	155
36	SpiroSmart. , 2012, , .		154

#	Article	IF	Citations
37	Accurate and privacy preserving cough sensing using a low-cost microphone. , 2011, , .		152
38	ARMC4 Mutations Cause Primary Ciliary Dyskinesia with Randomization of Left/Right Body Asymmetry. American Journal of Human Genetics, 2013, 93, 357-367.	6.2	150
39	Lung Clearance Index as an Outcome Measure for Clinical Trials in Young Children with Cystic Fibrosis. A Pilot Study Using Inhaled Hypertonic Saline. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 456-460.	5.6	147
40	Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 529-539.	5.6	147
41	Clinical Practice Guidelines From the Cystic Fibrosis Foundation for Preschoolers With Cystic Fibrosis. Pediatrics, 2016, 137, .	2.1	140
42	Cystic fibrosis pulmonary exacerbations. Journal of Pediatrics, 2006, 148, 259-264.	1.8	139
43	Guidelines for Implementation of Cystic Fibrosis Newborn Screening Programs: Cystic Fibrosis Foundation Workshop Report. Pediatrics, 2007, 119, e495-e518.	2.1	139
44	Exome Sequencing Identifies Mutations in CCDC114 as a Cause of Primary Ciliary Dyskinesia. American Journal of Human Genetics, 2013, 92, 99-106.	6.2	138
45	Clinical Features and Associated Likelihood of Primary Ciliary Dyskinesia in Children and Adolescents. Annals of the American Thoracic Society, 2016, 13, 1305-1313.	3.2	138
46	Lumacaftor/Ivacaftor in Patients Aged 6â€“11 Years with Cystic Fibrosis and Homozygous for F508del-CFTR. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 912-920.	5.6	138
47	Return of FEV₁ after pulmonary exacerbation in children with cystic fibrosis. Pediatric Pulmonology, 2010, 45, 127-134.	2.0	120
48	Improved survival among young patients with cystic fibrosis. Journal of Pediatrics, 2003, 142, 631-636.	1.8	116
49	Primary Ciliary Dyskinesia: Longitudinal Study of Lung Disease by Ultrastructure Defect and Genotype. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 190-198.	5.6	116
50	Pseudomonas aeruginosa In Vitro Phenotypes Distinguish Cystic Fibrosis Infection Stages and Outcomes. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 289-297.	5.6	113
51	Early anti-pseudomonal acquisition in young patients with cystic fibrosis: Rationale and design of the EPIC clinical trial and observational study,. Contemporary Clinical Trials, 2009, 30, 256-268.	1.8	110
52	Pseudomonas acquisition in young patients with cystic fibrosis: pathophysiology, diagnosis, and management. Current Opinion in Pulmonary Medicine, 2003, 9, 492-497.	2.6	109
53	Potential impact of newborn screening for cystic fibrosis on child survival: A systematic review and analysis. Journal of Pediatrics, 2006, 149, 362-366.	1.8	98
54	Multiple-Breath Washout as a Lung Function Test in Cystic Fibrosis. A Cystic Fibrosis Foundation Workshop Report. Annals of the American Thoracic Society, 2015, 12, 932-939.	3.2	96

#	Article	IF	Citations
55	Risk factors for lung function decline in a large cohort of young cystic fibrosis patients. Pediatric Pulmonology, 2015, 50, 763-770.	2.0	94
56	An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2â€“5â€¯years (KLIMB). Journal of Cystic Fibrosis, 2019, 18, 838-843.	0.7	94
57	Preschool Multiple-Breath Washout Testing. An Official American Thoracic Society Technical Statement. American Journal of Respiratory and Critical Care Medicine, 2018, 197, e1-e19.	5.6	92
58	Multicenter Evaluation of Infant Lung Function Tests as Cystic Fibrosis Clinical Trial Endpoints. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 1387-1397.	5.6	90
59	Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine,the, 2019, 7, 802-809.	10.7	89
60	Prospective evaluation of respiratory exacerbations in children with cystic fibrosis from newborn screening to 5â€¦years of age. Thorax, 2013, 68, 643-651.	5.6	83
61	Diagnosis of Cystic Fibrosis in Screened Populations. Journal of Pediatrics, 2017, 181, S33-S44.e2.	1.8	82
62	Risk factors for age at initial Pseudomonas acquisition in the cystic fibrosis epic observational cohort. Journal of Cystic Fibrosis, 2012, 11, 446-453.	0.7	78
63	Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonology, 2012, 47, 125-134.	2.0	78
64	Outcomes of Infants With Indeterminate Diagnosis Detected by Cystic Fibrosis Newborn Screening. Pediatrics, 2015, 135, e1386-e1392.	2.1	78
65	Efficiency of Pulmonary Administration of Tobramycin Solution for Inhalation in Cystic Fibrosis Using an Improved Drug Delivery System. Chest, 2003, 123, 28-36.	0.8	76
66	Azithromycin for Early Pseudomonas Infection in Cystic Fibrosis. The OPTIMIZE Randomized Trial. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 1177-1187.	5.6	75
67	Serum and lower respiratory tract drug concentrations after tobramycin inhalation in young children with cystic fibrosis. Journal of Pediatrics, 2001, 139, 572-577.	1.8	73
68	Endpoints for Clinical Trials in Young Children with Cystic Fibrosis. Proceedings of the American Thoracic Society, 2007, 4, 418-430.	3.5	71
69	Ivacaftor in Infants Aged 4 to <12 Months with Cystic Fibrosis and a Gating Mutation. Results of a Two-Part Phase 3 Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 585-593.	5.6	67
70	Bronchiectasis and Pulmonary Exacerbations in Children and Young Adults With Cystic Fibrosis. Chest, 2011, 140, 178-185.	0.8	66
71	Impact of Sustained Eradication of NewPseudomonas aeruginosaInfection on Long-term Outcomes in Cystic Fibrosis. Clinical Infectious Diseases, 2015, 61, 707-715.	5.8	66
72	Disease-specific Reference Equations for Lung Function in Patients with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2005, 172, 885-891.	5.6	65

#	Article	IF	Citations
73	Pseudomonas aeruginosa Phenotypes Associated With Eradication Failure in Children With Cystic Fibrosis. Clinical Infectious Diseases, 2014, 59, 624-631.	5.8	64
74	Early Life Growth Trajectories in Cystic Fibrosis are Associated with Pulmonary Function at Age 6 Years. Journal of Pediatrics, 2015, 167, 1081-1088.e1.	1.8	63
75	Approach to eradication of initial Pseudomonas aeruginosa infection in children with cystic fibrosis. Pediatric Pulmonology, 2007, 42, 751-756.	2.0	60
76	Home nebulizer use among patients with cystic fibrosis. Journal of Pediatrics, 1998, 132, 125-131.	1.8	59
77	Clinical outcomes after initial pseudomonas acquisition in cystic fibrosis. Pediatric Pulmonology, 2015, 50, 42-48.	2.0	59
78	Nutritional Effects of Long-Term Gastrostomy Feedings in Children With Cystic Fibrosis. Journal of the American Dietetic Association, 1999, 99, 191-194.	1.1	58
79	Effect of choice of reference equation on analysis of pulmonary function in cystic fibrosis patients. Pediatric Pulmonology, 2001, 31, 227-237.	2.0	57
80	Fine Particulate Matter Exposure and Initial Pseudomonas aeruginosa Acquisition in Cystic Fibrosis. Annals of the American Thoracic Society, 2015, 12, 385-391.	3.2	57
81	The Prevalence of Ibuprofen-sensitive Asthma in Children: A Randomized Controlled Bronchoprovocation Challenge Study. Journal of Pediatrics, 2005, 147, 233-238.	1.8	55
82	Diagnostic yield of nasal scrape biopsies in primary ciliary dyskinesia: A multicenter experience. Pediatric Pulmonology, 2011, 46, 483-488.	2.0	52
83	Socioeconomic Status, Smoke Exposure, and Health Outcomes in Young Children With Cystic Fibrosis. Pediatrics, 2017, 139, .	2.1	52
84	Baseline Characteristics and Factors Associated With Nutritional and Pulmonary Status at Enrollment in the Cystic Fibrosis EPIC Observational Cohort. Pediatric Pulmonology, 2010, 45, 934-944.	2.0	51
85	Revision Surgeries Are Associated With Significant Increased Risk of Subsequent Cerebrospinal Fluid Shunt Infection. Pediatric Infectious Disease Journal, 2012, 31, 551-556.	2.0	51
86	Early intervention studies in infants and preschool children with cystic fibrosis: are we ready?. European Respiratory Journal, 2013, 42, 527-538.	6.7	49
87	An Overview of Endpoints for Cystic Fibrosis Clinical Trials: One Size Does Not Fit All. Proceedings of the American Thoracic Society, 2007, 4, 299-301.	3.5	48
88	Characterization of Inpatient Cystic Fibrosis Pulmonary Exacerbations. Pediatrics, 2017, 139, .	2.1	48
89	Restoring Pulmonary and Sleep Services as the COVID-19 Pandemic Lessens. From an Association of Pulmonary, Critical Care, and Sleep Division Directors and American Thoracic Societyâ€“coordinated Task Force. Annals of the American Thoracic Society, 2020, 17, 1343-1351.	3.2	47
90	Forced Expiratory Volume in 1 Second Variability Helps Identify Patients with Cystic Fibrosis at Risk of Greater Loss of Lung Function. Journal of Pediatrics, 2016, 169, 116-121.e2.	1.8	44

#	Article	IF	Citations
91	Antibiotic treatment of signs and symptoms of pulmonary exacerbations: A comparison by care site. Pediatric Pulmonology, 2015, 50, 431-440.	2.0	43
92	Update on cystic fibrosis epidemiology. Current Opinion in Pulmonary Medicine, 2004, 10, 510-514.	2.6	42
93	Pharmacogenomic testing to prevent aminoglycoside-induced hearing loss in cystic fibrosis patients: potential impact on clinical, patient, and economic outcomes. Genetics in Medicine, 2007, 9, 695-704.	2.4	42
94	Lung function distinguishes preschool children with CF from healthy controls in a multiâ€€enter setting. Pediatric Pulmonology, 2012, 47, 597-605.	2.0	41
95	Season is associated with Pseudomonas aeruginosa acquisition in young children with cystic fibrosis. Clinical Microbiology and Infection, 2013, 19, E483-E489.	6.0	41
96	The impact of switching to the new global lung function initiative equations on spirometry results in the UK CF Registry. Journal of Cystic Fibrosis, 2014, 13, 319-327.	0.7	41
97	Accuracy of Nasal Nitric Oxide Measurement as a Diagnostic Test for Primary Ciliary Dyskinesia: A Systematic Review and Meta-Analysis. Annals of the American Thoracic Society, 2017, 14, 1184-1196.	3.2	41
98	Treatment and Microbiology of Repeated Cerebrospinal Fluid Shunt Infections in Children. Pediatric Infectious Disease Journal, 2011, 30, 731-735.	2.0	40
99	Sputum Tobramycin Concentrations in Cystic Fibrosis Patients with Repeated Administration of Inhaled Tobramycin. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2013, 26, 69-75.	1.4	39
100	Longitudinal development of initial, chronic and mucoid Pseudomonas aeruginosa infection in young children with cystic fibrosis. Journal of Cystic Fibrosis, 2018, 17, 341-347.	0.7	38
101	Risk Factors for Gaps in Care during Transfer from Pediatric to Adult Cystic Fibrosis Programs in the United States. Annals of the American Thoracic Society, 2018, 15, 234-240.	3.2	37
102	Chest computed tomography: a validated surrogate endpoint of cystic fibrosis lung disease?. European Respiratory Journal, 2013, 42, 844-857.	6.7	36
103	Cystic Fibrosis Diagnosis and Newborn Screening. Pediatric Clinics of North America, 2016, 63, 599-615.	1.8	35
104	Overview of published evidence on outcomes with early diagnosis from large US observational studies. Journal of Pediatrics, 2005, 147, S11-S14.	1.8	34
105	Association of intraventricular hemorrhage secondary to prematurity with cerebrospinal fluid shunt surgery in the first year following initial shunt placement. Journal of Neurosurgery: Pediatrics, 2012, 9, 54-63.	1.3	34
106	Small airway involvement in cystic fibrosis lung disease: Routine spirometry as an early and sensitive marker. Pediatric Pulmonology, 2013, 48, 1081-1088.	2.0	33
107	Prophylactic anti-staphylococcal antibiotics for cystic fibrosis. The Cochrane Library, 2017, 4, CD001912.	2.8	33
108	Analysis of the associations between lung function and clinical features in preschool children with Cystic Fibrosis. Pediatric Pulmonology, 2012, 47, 574-581.	2.0	32

#	Article	IF	Citations
109	Survey of clinical infant lung function testing practices. Pediatric Pulmonology, 2014, 49, 126-131.	2.0	32
110	Changes in Lung Clearance Index in Preschool-aged Patients with Cystic Fibrosis Treated with Ivacaftor (GOAL): A Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 526-528.	5.6	32
111	Cleaning home nebulizers used by patients with cystic fibrosis: is rinsing with tap water enough?. Journal of Hospital Infection, 2001, 49, 229-230.	2.9	31
112	Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa in cystic fibrosis. Pediatric Pulmonology, 2013, 48, 943-953.	2.0	31
113	The expanding phenotype of OFD1 â€related disorders: Hemizygous lossâ€ofâ€function variants in three patients with primary ciliary dyskinesia. Molecular Genetics & Genomic Medicine, 2019, 7, e911.	1.2	31
114	Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial. Journal of Cystic Fibrosis, 2013, 12, 147-153.	0.7	30
115	Air pollution exposure is associated with MRSA acquisition in young U.S. children with cystic fibrosis. BMC Pulmonary Medicine, 2017, 17, 106.	2.0	30
116	An Official American Thoracic Society/European Respiratory Society Workshop Report: Evaluation of Respiratory Mechanics and Function in the Pediatric and Neonatal Intensive Care Units. Annals of the American Thoracic Society, 2016, 13, S1-S11.	3.2	29
117	Inhaled hypertonic saline in infants and toddlers with cystic fibrosis: shortâ€term tolerability, adherence, and safety. Pediatric Pulmonology, 2011, 46, 666-671.	2.0	28
118	Prevalence of cystic fibrosis pathogens in the oropharynx of healthy children and implications for cystic fibrosis care. Journal of Cystic Fibrosis, 2012, 11, 456-457.	0.7	28
119	Chronic Azithromycin Use in Cystic Fibrosis and Risk of Treatment-Emergent Respiratory Pathogens. Annals of the American Thoracic Society, 2018, 15, 702-709.	3.2	28
120	Early Childhood Risk Factors for Decreased FEV1at Age 6-7 Years in Young Children with Cystic Fibrosis. Annals of the American Thoracic Society, 2015, 12, 150819115840007.	3.2	25
121	Comparison of Multiple Breath Washout and Spirometry in Children with Primary Ciliary Dyskinesia and Cystic Fibrosis and Healthy Controls. Annals of the American Thoracic Society, 2020, 17, 1085-1093.	3.2	25
122	Early Respiratory Bacterial Detection and Antistaphylococcal Antibiotic Prophylaxis in Young Children with Cystic Fibrosis. Annals of the American Thoracic Society, 2018, 15, 42-48.	3.2	24
123	Association of lung function, chest radiographs and clinical features in infants with cystic fibrosis. European Respiratory Journal, 2013, 42, 1545-1552.	6.7	23
124	Initial evaluation of the Parent Cystic Fibrosis Questionnaireâ€"Revised (CFQ-R) in infants and young children. Journal of Cystic Fibrosis, 2015, 14, 403-411.	0.7	23
125	Tracking lung function on any phone. , 2013, , .		22
126	Differential Geographical Risk of Initial Pseudomonas aeruginosa Acquisition in Young US Children With Cystic Fibrosis. American Journal of Epidemiology, 2014, 179, 1503-1513.	3.4	22

#	Article	IF	Citations
127	Lung function from infancy to preschool in a cohort of children with cystic fibrosis. European Respiratory Journal, 2013, 41, 60-66.	6.7	21
128	Early childhood wheezing is associated with lower lung function in cystic fibrosis. Pediatric Pulmonology, 2014, 49, 745-750.	2.0	21
129	Evaluation of Microbial Bacterial and Fungal Diversity in Cerebrospinal Fluid Shunt Infection. PLoS ONE, 2014, 9, e83229.	2.5	21
130	The effect of inhaled hypertonic saline on lung structure in children aged 3â€“6 years with cystic fibrosis (SHIP-CT): a multicentre, randomised, double-blind, controlled trial. Lancet Respiratory Medicine,the, 2022, 10, 669-678.	10.7	20
131	Decline in lung function does not predict future decline in lung function in cystic fibrosis patients. Pediatric Pulmonology, 2015, 50, 856-862.	2.0	19
132	Pulmonary exacerbations and parentâ€reported outcomes in children <6 years with cystic fibrosis. Pediatric Pulmonology, 2015, 50, 236-243.	2.0	19
133	Association of meteorological and geographical factors and risk of initialPseudomonas aeruginosaacquisition in young children with cystic fibrosis. Epidemiology and Infection, 2016, 144, 1075-1083.	2.1	19
134	Opportunities and pitfalls of registry data for clinical research. Paediatric Respiratory Reviews, 2013, 14, 141-145.	1.8	18
135	Seasonality of acquisition of respiratory bacterial pathogens in young children with cystic fibrosis. BMC Infectious Diseases, 2017, 17, 411.	2.9	16
136	Caregiver Burden Due to Pulmonary Exacerbations in Patients with Cystic Fibrosis. Journal of Pediatrics, 2019, 215, 164-171.e2.	1.8	16
137	Cri du Chat Syndrome and Primary Ciliary Dyskinesia: A Common Genetic Cause on Chromosome 5p. Journal of Pediatrics, 2014, 165, 858-861.	1.8	15
138	Serology as a diagnostic tool for predicting initialPseudomonas aeruginosa acquisition in childrenwith cystic fibrosis. Journal of Cystic Fibrosis, 2014, 13, 542-549.	0.7	15
139	Predictors of pulmonary exacerbation treatment in cystic fibrosis. Journal of Cystic Fibrosis, 2020, 19, 407-414.	0.7	15
140	Few Patient, Treatment, and Diagnostic or Microbiological Factors, Except Complications and Intermittent Negative Cerebrospinal Fluid (CSF) Cultures During First CSF Shunt Infection, Are Associated With Reinfection. Journal of the Pediatric Infectious Diseases Society, 2014, 3, 15-22.	1.3	14
141	Reproducibility of spirometry during cystic fibrosis pulmonary exacerbations. Pediatric Pulmonology, 2008, 43, 1142-1146.	2.0	13
142	Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis. Journal of Cystic Fibrosis, 2016, 15, 386-391.	0.7	13
143	Resilience in adolescents and young adults with cystic fibrosis: A pilot feasibility study of the promoting resilience in stress managementÂintervention. Pediatric Pulmonology, 2020, 55, 638-645.	2.0	13
144	A Phase 3, Open-Label Study of Lumacaftor/Ivacaftor in Children 1 to Less Than 2 Years of Age with Cystic Fibrosis Homozygous for F508del-CFTR. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 1239-1247.	5.6	13

#	Article	IF	Citations
145	Evolution of airway microbiology in the infant with cystic fibrosis: role of nonpseudomonal and pseudomonal pathogens. Seminars in Respiratory Infections, 1992, 7, 158-67.	1.3	12
146	Inflammasome Genetic Variants, Macrophage Function, and Clinical Outcomes in Cystic Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2021, 65, 157-166.	2.9	11
147	Health workersâ€™ perspectives of a mobile health tool to improve diagnosis and management of paediatric acute respiratory illnesses in Uganda: a qualitative study. BMJ Open, 2021, 11, e049708.	1.9	11
148	Initial development and pilot testing of observer-reported outcomes (ObsROs) for children with cystic fibrosis ages 0â€“11 years. Journal of Cystic Fibrosis, 2018, 17, 680-686.	0.7	10
149	Association Between Number of Intravenous Antipseudomonal Antibiotics and Clinical Outcomes of Pediatric Cystic Fibrosis Pulmonary Exacerbations. Clinical Infectious Diseases, 2021, 73, 1589-1596.	5.8	10
150	Age-related heterogeneity in dental caries and associated risk factors in individuals with cystic fibrosis ages 6â€“20 years: A pilot study. Journal of Cystic Fibrosis, 2018, 17, 747-759.	0.7	9
151	Pediatric lung function testing during a pandemic: An international perspective. Paediatric Respiratory Reviews, 2020, 36, 106-108.	1.8	9
152	Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemporary Clinical Trials, 2013, 36, 99-105.	1.8	8
153	Socioeconomic and Environmental Risk Factors for Pediatric Asthma in an American Indian Community. Academic Pediatrics, 2019, 19, 631-637.	2.0	8
154	Association of Inhaled Antibiotics in Addition to Standard Intravenous Therapy and Outcomes of Pediatric Inpatient Pulmonary Exacerbations. Annals of the American Thoracic Society, 2020, 17, 1590-1598.	3.2	8
155	Oral antibiotic prescribing patterns for treatment of pulmonary exacerbations in two large pediatric CF centers. Pediatric Pulmonology, 2020, 55, 3400-3406.	2.0	8
156	Effect of Concomitant Azithromycin and Tobramycin Use on Cystic Fibrosis Pulmonary Exacerbation Treatment. Annals of the American Thoracic Society, 2021, 18, 266-272.	3.2	8
157	Club cell secretory protein and lung function in children with cystic fibrosis. Journal of Cystic Fibrosis, 2022, 21, 811-820.	0.7	8
158	Aerosolized Antibiotics for Bacterial Lower Airway Infections. Clinical Pulmonary Medicine, 1997, 4, 101-112.	0.3	7
159	Application of multiple event analysis as an alternative approach to studying pulmonary exacerbations as an outcome measure. Journal of Cystic Fibrosis, 2020, 19, 114-118.	0.7	7
160	Innovating and adapting in pediatric pulmonology and sleep medicine during the COVIDâ€19 pandemic: ATS pediatric assembly web committee consensus statement for initial COVIDâ€19 virtual response. Pediatric Pulmonology, 2021, 56, 539-550.	2.0	7
161	Prophylactic anti-staphylococcal antibiotics for cystic fibrosis. The Cochrane Library, 2020, 2020, CD001912.	2.8	7
162	AEROSOLIZED ANTIBIOTICS FOR BACTERIAL LOWER AIRWAY INFECTIONS. Infectious Diseases in Clinical Practice, 1998, 7, 66-79.	0.3	6

#	Article	IF	Citations
163	WS01.5 An open-label study of the safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2 to 5 years with cystic fibrosis and a CFTR gating mutation: The KIWI study. Journal of Cystic Fibrosis, 2015, 14, S2.	0.7	6
164	Spirometry-Assisted High Resolution Chest Computed Tomography in Children: Is it Worth the Effort?. Current Problems in Diagnostic Radiology, 2018, 47, 14-18.	1.4	6
165	Narrowing in on Early Cystic Fibrosis Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 1082-1084.	5.6	5
166	Yoga as a Therapy for Adolescents and Young Adults with Cystic Fibrosis: A Pilot Study. Global Advances in Health and Medicine, 2015, 4, 32-36.	1.6	5
167	Climate change and lung health: the challenge for a new president. Thorax, 2017, 72, 295-296.	5.6	5
168	Primary ciliary dyskinesia: keep it on your radar. Thorax, 2018, 73, 101-102.	5.6	5
169	Clinical Outcomes of Antipseudomonal versus Other Antibiotics among Children with Cystic Fibrosis without Pseudomonas aeruginosa. Annals of the American Thoracic Society, 2022, 19, 1320-1327.	3.2	5
170	Therapeutic bilateral lung lavage in a child with pulmonary alveolar proteinosis. Pediatric Critical Care Medicine, 2010, 11, e28-e31.	0.5	4
171	Palivizumab and Long-term Outcomes in Cystic Fibrosis. Pediatrics, 2019, 144, e20183495.	2.1	4
172	Acute hyperglycaemia in cystic fibrosis pulmonary exacerbations. Endocrinology, Diabetes and Metabolism, 2021, 4, e00208.	2.4	4
173	Association of Intensity of Antipseudomonal Antibiotic Therapy With Risk of Treatment-Emergent Organisms in Children With Cystic Fibrosis and Newly Acquired Pseudomonas Aeruginosa. Clinical Infectious Diseases, 2021, 73, 987-993.	5.8	4
174	Elementary, My Dear Watson! The Accumulating Evidence for the Lung Clearance Index in Monitoring Early Cystic Fibrosis Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 1131-1132.	5.6	3
175	Comparing encounter-based and annualized chronic pseudomonas infection definitions in cystic fibrosis. Journal of Cystic Fibrosis, 2022, 21, 40-44.	0.7	3
176	Emergence of Oseltamivir-Resistant Pandemic H1N1 in an Immunocompetent Child with Severe Status Asthmaticus. Journal of Asthma, 2011, 48, 572-575.	1.7	2
177	Appropriate Pediatric Spirometry Reference Equations and Interpretation. Pediatric, Allergy, Immunology, and Pulmonology, 2011, 24, 63-68.	0.8	2
178	Respiratory Manifestations. , 2008, , 871-887.		1
179	Monitoring of Structure and Function in Early Cystic Fibrosis Lung Disease. Pediatric, Allergy, Immunology, and Pulmonology, 2011, 24, 133-137.	0.8	1
180	Climate change and lung health: presidential failure, professional responsibility. Thorax, 2019, 74, 627-628.	5.6	1

#	Article	IF	Citations
181	Associating antimicrobial susceptibility testing with clinical outcomes in cystic fibrosis: More rigor and less frequency?. Journal of Cystic Fibrosis, 2019, 18, 159-160.	0.7	1
182	Initial Development of a Mobile Health Tool to Objectively Measure Respiratory Distress in Infants. , 2019, , .		1
183	S63â€…Ivacaftor in 4- to <6-month-old infants with cystic fibrosis and a gating mutation: results of a 2-part, single-arm, Phase 3 study. , 2021, , .		1
184	Accounting for population structure in genetic studies of cystic fibrosis. Human Genetics and Genomics Advances, 2022, 3, 100117.	1.7	1
185	Cystic Fibrosis Diseaseâ€“specific Centiles in 2000 and 2005. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 1047a-1047a.	5.6	0
186	Pseudomonas aeruginosa eradication: Finally moving the needle?. Journal of Cystic Fibrosis, 2017, 16, 309-310.	0.7	0
187	S96â€…An open-label extension (ext) study of lumacaftor/ivacaftor (lum/iva) therapy in patients aged 6 to 11 years with cystic fibrosis (cf) homozygous for f508del-cftr. , 2017, , .		0
188	Treating Cystic Fibrosis Pulmonary Exacerbations: In the Hospital with a Physician or at Home under Your Own Supervision?. Annals of the American Thoracic Society, 2018, 15, 169-170.	3.2	0
189	Reply to Johnson: Improve Pulmonary Function Test Reporting. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 138-139.	5.6	0
190	Treating the Airway Consequences of Cystic Fibrosis Transmembrane Conductance Regulator Dysfunction. Seminars in Respiratory and Critical Care Medicine, 2019, 40, 751-761.	2.1	0
191	Tidal Changes in Respiratory Resistance in Children with Cystic Fibrosis. , 2019, , .		0
192	Sensitivity of Multiple Breath Washout and Spirometry for Detection of Early Lung Disease in Children with Primary Ciliary Dyskinesia and Cystic Fibrosis: A Multicenter Study. , 2019, , .		0
193	Comparison of Longitudinal Clinical Outcomes in Primary Ciliary Dyskinesia and Cystic Fibrosis. , 2020, , .		0
194	Association of Genotype and Structural Lung Disease in a Cohort of Children with PCD. , 2020, , .		0
195	Survey and electronic health recordâ€based medication use agreement in children with cystic fibrosis: A retrospective crossâ€sectional study. International Journal of Paediatric Dentistry, 2021, 31, 247-253.	1.8	0
196	Therapies Used for Primary Ciliary Dyskinesia in North American Children. , 2021, , .		0
197	Upper Airway Manifestations of Primary Ciliary Dyskinesia During Childhood. , 2021, , .		0
198	Relationship Between Genotype and Laterality Defects in Primary Ciliary Dyskinesia. , 2021, , .		0

#	Article	IF	Citations
199	Severity of Neonatal Respiratory Distress and Future Lung Function in Children with Primary Ciliary Dyskinesia. , 2021, , .		0
200	Transcriptional and Post-Transcriptional Strategies in Neuroendocrine Gene Expression. , 1988, 5, 317-334.		0
201	Selection and Appropriate Use of Spirometric Reference Equations for the Pediatric Population. Respiratory Medicine, 2015, , 181-193.	0.1	0
202	Application of gap time analysis with flexible hazards to pulmonary exacerbations in the EPIC observational study. Biometrical Journal, 2022, , .	1.0	0
203	Building for the Future: Establishment of the Primary Ciliary Dyskinesia Foundation Clinical Registry. , 2022, , .		0
204	Progression of Upper Airway Manifestations in Primary Ciliary Dyskinesia Throughout Childhood. , 2022, , .		0
205	Relationship Between Genotype/Ultrastructural Defect and Neonatal Respiratory Distress in Primary Ciliary Dyskinesia. , 2022, , .		0
206	Performance and Usability of a New Mobile Phone Application in Assessing Respiratory Rate in Pediatric Patients. , 2022, , .		0
207	Factors Associated with Abnormal Lung Function in Adolescents With and Without HIV in Nairobi, Kenya. , 2022, , .		0
208	COMBATing airway inflammation in infants with cystic fibrosis. Lancet Respiratory Medicine,the, 2022, , .	10.7	0